Implementation of Lead Safety Recommendations

Background: The Medtronic Sprint Fidelis (SF) implantable cardioverter defibrillator (ICD; Medtronic Inc., Minneapolis, MN, USA) lead has a higher than expected failure rate. Because of patient safety, Medtronic announced two advisories consisting of (1) adjustments in device settings (October 2007)...

Full description

Saved in:
Bibliographic Details
Published inPacing and clinical electrophysiology Vol. 33; no. 4; pp. 431 - 436
Main Authors VAN REES, JOHANNES B., BORLEFFS, C. JAN WILLEM, BAX, JEROEN J., NAGTEGAAL, ELS M., VAN DER VELDE, ENNO T., VAN ERVEN, LIESELOT, SCHALIJ, MARTIN J.
Format Journal Article
LanguageEnglish
Published Malden, USA Blackwell Publishing Inc 01.04.2010
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background: The Medtronic Sprint Fidelis (SF) implantable cardioverter defibrillator (ICD; Medtronic Inc., Minneapolis, MN, USA) lead has a higher than expected failure rate. Because of patient safety, Medtronic announced two advisories consisting of (1) adjustments in device settings (October 2007) and (2) installation of a lead integrity algorithm (May 2008). The objective of this study was to evaluate the effect of Medtronic's announcements on patient safety. Methods: To comply with the advisories, two clinical evaluations were conducted. The effect of the advisories was assessed by the lead failure rate and the occurrence of inappropriate shocks due to lead failure. Three periods were distinguished in the comparison of event rates: lead implantation to advisory 1 (period A), in‐between both advisories (period B), and advisory 2 to follow‐up (period C). Results: Since 2004, 372 patients received a Medtronic ICD and SF lead and were followed from first implant (December 2004) to April 2009. Cumulative incidence rate of lead failure was 3.6%[95% confidence interval (CI) 1.6–5.6] at 21 months and increased to 11.0% (95% CI 6.1–15.9) at 42 months. After implementation of both advisories, the occurrence of inappropriate shocks due to lead failure decreased from 1.5 (95% CI 0.59, 3.00) per 100 lead‐years in period A to 0.8 (95% CI 0.02, 4.25) per 100 lead‐years in period C. Conclusion: The current study demonstrates that despite an increasing risk for SF lead failure, implementation of the advisories decreased the occurrence of inappropriate shocks due to lead failure. (PACE 2010; 431–436)
Bibliography:ark:/67375/WNG-ZNG8XNCL-S
istex:37ADECE421BE97C14079BB8E7C8B550FDC4B10C5
ArticleID:PACE2622
Conflicts of interest: Professor Schalij received research grants from Biotronik, Medtronic and Boston Scientific. Professor Bax received research grants from GE Healthcare, BMS medical imaging, St. Jude, Medtronic, Boston Scientific, Biotronik, and Edwards Lifesciences.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0147-8389
1540-8159
DOI:10.1111/j.1540-8159.2009.02622.x